Navigation Links
New discovery may lead to effective prevention and treatment of graft-versus-host dsease
Date:4/1/2012

Bethesda, MD -- A new discovery in mice may lead to new treatments that could make bone marrow transplants more likely to succeed and to be significantly less dangerous. According to new research findings published in the Journal of Leukocyte Biology (https://www.jleukbio.org) Brazilian scientists may have found a way to prevent the immune system from attacking transplant grafts and damaging the host's own cells after a bone marrow transplant.

Specifically, they found that a receptor for a mediator of the inflammatory process, known as platelet activating factor plays a crucial role in the development of graft-versus-host disease. Platelet activating factor receptor appears to contribute to the attraction of immune cells that lead to graft-versus-host disease. When this mechanism was blocked, there was reduced tissue damage and mortality.

"Platelet activating factor receptor antagonists may decrease suffering caused by graft-versus-host disease in patients undergoing bone marrow transplant," said Vanessa Pinho, Ph.D., a researcher involved in the work from the Departamento de Morfologia, Instituto de Ciencias Biologicas, Universidade Federal de Minas Gerais in Brazil. "As graft-versus-host disease also may decrease quality of life, patients treated with platelet activating factor receptor antagonists may live longer and with better quality of life."

To make this discovery, scientists induced graft-versus-host disease by transferring cells between mice which were genetically incompatible. In mice subjected to graft-versus-host disease, there was significant injury to target organs, especially the liver and the intestine. In mice that received cells from genetically modified mice bred to not have platelet activating factor receptors, or in mice treated with platelet activating factor receptor antagonist, there was reduced tissue injury and reduced lethality.

"Immune rejection is o
'/>"/>

Contact: Cody Mooneyhan
cmooneyhan@faseb.org
301-634-7104
Federation of American Societies for Experimental Biology
Source:Eurekalert

1

GOOD

Page: 1 2

Related biology news :

1. Tales from the crypt lead researchers to cancer discovery
2. Breast cancer risk gene discovery fast tracked by new technology
3. Discovery offers insight into treating viral stomach flu
4. Unexpected discovery reveals a new mechanism for how the cerebellum extracts signal from noise
5. Discovery provides blueprint for new drugs that can inhibit hepatitis C virus
6. Annual Drug Discovery Conferences Being Held in Boston MA, Spring 2012
7. Discovery of a molecule that initiates maturation of mammalian eggs can lead to more IVF pregnancies
8. A*STAR scientists make groundbreaking discovery on stem cell regulation
9. A biodiversity discovery that was waiting in the wings -- wasp wings, that is
10. OHSU discovery may someday lead to prevention and treatment of sudden infant death syndrome
11. Notre Dame researchers report fundamental malaria discovery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... of biomass experts , Where? Copenhagen, ... 03-07 June 2013 , Why? ... assessment, market and policy developments, manufacturing and installation, drawing ... benefiting from its 2013 edition from a record of ... countries, more than 240 plenary and oral presentations, more ...
(Date:5/20/2013)... Minnesota Medical School researchers from the Masonic Cancer Center, ... Tumor Program, have developed a new mouse model of ... to discover new genes and gene pathways driving this ... week in the journal Nature Genetics . , ... lab of David Largaespada, Ph.D., professor in the Medical ...
(Date:5/20/2013)... DIEGO (May 20, 2013) - A novel ... headline the groundbreaking research that will be unveiled at ... Conference (NBC). The meeting takes place Monday, May 20 ... Hotel and Marina. , "The main goal of ... fight against a pathogen that causes the disease", explained ...
Breaking Biology News(10 mins):21st European Biomass Conference and Exhibition 221st European Biomass Conference and Exhibition 321st European Biomass Conference and Exhibition 4U of M researchers develop model for better testing, targeting of MPNST 2Germ-fighting vaccine system makes great strides in delivery 2
... parts of the shark and are often removed from the body, ... practice, many countries allow the fins to be landed detached from ... per cent of the total shark catch. New University of British ... A study published this week in the journal ...
... to their doctor for a blood test generally has to ... of uncertainty can make patients anxious especially in critical ... it takes so long for laboratories to analyze samples is ... Each sample must be accompanied by meticulous records, so lab ...
... Md. (March 1, 2012)The American Physiology Society (APS) has announced ... experimental animals and the sex or gender of humans used ... 13 peer-reviewed journals. This notable requirement for all research study ... be presented in an editorial, " In Pursuit of Scientific ...
Cached Biology News:Law that regulates shark fishery is too liberal: UBC study 2'Labor der Zukunft' -- Tomorrow's laboratory technology 2'Labor der Zukunft' -- Tomorrow's laboratory technology 3APS issues new policy requiring identification of sex or gender in reporting scientific research 2APS issues new policy requiring identification of sex or gender in reporting scientific research 3
(Date:5/21/2013)... The Formulate Fusion Fabric Display ... and marketing teams looking for a fully-functional package for their ... “everything you’ll need to put together a stunning and eye-catching ... a number of displays and accessories that can be quickly ... 20 feet in size. These components vary from kit to ...
(Date:5/20/2013)... -- , Collaboration with the U.S. ... in treatment of mastitis , Major ... begin in the second half 2013 ... Limited (ASX: POH, OTCQX: PPGNY) will collaborate with ... (ARS) to develop and trial products targeting the serious ...
(Date:5/20/2013)... Pa (PRWEB) May 20, 2013 Oven ... with ramp/soak capabilities. The 5R6-900 benchtop controller has ... the device can be plugged into the wall as ... power supply. This distinctive detail makes the device unique, ... , The laboratory temperature controller can also be used ...
(Date:5/20/2013)... -- Today, at the American Psychiatric Association (APA) Meeting ... James McGough , M.D., M.S., principal investigator and ... Neuroscience and Human Behavior and David Geffen ... California Los Angeles (UCLA), and director of clinical teaching ... at UCLA, presented the results of a Phase I ...
Breaking Biology Technology:GLM Displays Announces All-in-One Formulate Fusion Fabric Display Kit 2Phosphagenics Signs Research Agreement with the Agricultural Research Service 2New Laboratory Temperature Controller by Oven Industries 2Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 2Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 3Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 4Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 5
... People Living with ... Fibromyalgia -, INDIANAPOLIS, Oct. ... Martha Beck, one day became a seemingly,endless cycle of widespread pain, fatigue, ... answer to the painful,symptoms she was experiencing before she finally received a ...
... Data on Ceftaroline, a Novel, Broad-Spectrum Cephalosporin in,Development ... and,Community Acquired Pneumonia (CAP), WASHINGTON, Oct. 27, ... presented a detailed analysis of CANVAS I, a,globally ... 48th,Annual Interscience Conference on Antimicrobial Agents and Chemotherapy ...
... Today to ... Discuss Results, BIRMINGHAM, ... announced results of an,exploratory Phase 2 trial of intravenous (i.v.) peramivir, ... The Phase 2 trial compared the efficacy and,safety of five days ...
Cached Biology Technology:From Pain to Unexpected Fame: One Woman's Journey to Know Fibro 2From Pain to Unexpected Fame: One Woman's Journey to Know Fibro 3From Pain to Unexpected Fame: One Woman's Journey to Know Fibro 4From Pain to Unexpected Fame: One Woman's Journey to Know Fibro 5Positive Study Results for Ceftaroline Phase III Clinical Study for the Treatment of Complicated Skin and Skin Structure Infections Presented at ICAAC / IDSA 2Positive Study Results for Ceftaroline Phase III Clinical Study for the Treatment of Complicated Skin and Skin Structure Infections Presented at ICAAC / IDSA 3Positive Study Results for Ceftaroline Phase III Clinical Study for the Treatment of Complicated Skin and Skin Structure Infections Presented at ICAAC / IDSA 4Positive Study Results for Ceftaroline Phase III Clinical Study for the Treatment of Complicated Skin and Skin Structure Infections Presented at ICAAC / IDSA 5Positive Study Results for Ceftaroline Phase III Clinical Study for the Treatment of Complicated Skin and Skin Structure Infections Presented at ICAAC / IDSA 6Positive Study Results for Ceftaroline Phase III Clinical Study for the Treatment of Complicated Skin and Skin Structure Infections Presented at ICAAC / IDSA 7Positive Study Results for Ceftaroline Phase III Clinical Study for the Treatment of Complicated Skin and Skin Structure Infections Presented at ICAAC / IDSA 8BioCryst Reports Results From the First-Ever Completed Active-Controlled Phase 2 Study in Hospitalized Influenza 2BioCryst Reports Results From the First-Ever Completed Active-Controlled Phase 2 Study in Hospitalized Influenza 3BioCryst Reports Results From the First-Ever Completed Active-Controlled Phase 2 Study in Hospitalized Influenza 4BioCryst Reports Results From the First-Ever Completed Active-Controlled Phase 2 Study in Hospitalized Influenza 5BioCryst Reports Results From the First-Ever Completed Active-Controlled Phase 2 Study in Hospitalized Influenza 6
Normal human serum collected off the clot from healthy normal humans. Each donor unit is negative for anti-HIV 1&2, HIV-Ag, HCV, and HBsAg by FDA required tests...
sterile filtered, off the clot, all male donors, Total Protein: 4.5 to 8.5 g/dl...
Recombinant Mouse MMP-9, CF...
Human/Mouse/Rat JNK Pan Specific Affinity Purified PAb...
Biology Products: